The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
MOTION: A randomized, phase 3, placebo-controlled, double-blind study of vimseltinib (DCC-3014) for the treatment of tenosynovial giant cell tumor.
 
William D. Tap
Leadership - Atropos; Certis Oncology Solutions; Innovo Therapeutics
Stock and Other Ownership Interests - Atropos; Certis Oncology Solutions
Consulting or Advisory Role - Adcendo; Amgen; Ayala Pharmaceuticals; Bayer; C4 Therapeutics; Cogent Biosciences; Daiichi Sankyo; Deciphera; EMD Serono; Epizyme; Foghorn Therapeutics; Kowa Pharmaceutical; Lilly; Medpacto; Mundipharma; Servier
Research Funding - BioAtla; Blueprint Medicines; Daiichi Sankyo; Deciphera; Immune Design; Lilly; Novartis; Plexxikon; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Companion Diagnostic for CDK4 inhibitors - 14/854,329; Enigma and CDH18 as companion Diagnostics for CDK4 inhibition – SKI2016-021-03
 
Andrew J. Wagner
Honoraria - Deciphera
Consulting or Advisory Role - AADi; Boehringer Ingelheim; Cogent Biosciences; Daiichi Sankyo; Deciphera; Epizyme; Lilly; Mundipharma
Research Funding - AADi (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Foghorn Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Plexxikon (Inst); Rain Therapeutics (Inst)
 
Maitreyi G. Sharma
Employment - Deciphera
Stock and Other Ownership Interests - Deciphera
 
Marc Vallee
Employment - Deciphera
Stock and Other Ownership Interests - Deciphera
 
Mary F. Michenzie
Employment - Deciphera
Stock and Other Ownership Interests - Deciphera; Immunogen
 
Matthew L. Sherman
Employment - Deciphera; Pieris Pharmaceuticals
Leadership - Deciphera
Stock and Other Ownership Interests - Deciphera; Pieris Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Acceleron Pharma
Travel, Accommodations, Expenses - Deciphera; Pieris Pharmaceuticals
 
Rodrigo Ruiz-Soto
Employment - Deciphera
Stock and Other Ownership Interests - Deciphera; Immunogen
Patents, Royalties, Other Intellectual Property - I am an inventor in 3 patents with Immunogen, I transferred the rights to Immunogen. I have not received (and I will not receive) any royalties; I am an inventor in pending patents at Deciphera. I have transferred the rights to Deciphera, I have not received (and will not receive) any royalties
 
Silvia Stacchiotti
Honoraria - Aadi; GlaxoSmithKline; PharmaMar
Consulting or Advisory Role - Astex Pharmaceuticals; Bavarian Nordic; Bayer; Daiichi Sankyo; Deciphera; Epizyme; GlaxoSmithKline; Ikena Oncology; MaxiVax; Novartis; PharmaMar; Rain Therapeutics
Research Funding - Advenchen Laboratories (Inst); Amgen (Inst); Bayer (Inst); Blueprint Medicines (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Hutchison MediPharma (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); SpringWorks Therapeutics (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Michiel A.J. van de Sande
Honoraria - Daiichi Sankyo Europe GmbH
 
Hans Gelderblom
Research Funding - Daiichi (Inst); Deciphera (Inst); Ipsen (Inst); Novartis (Inst)